Cixutumumab is an anti-IGF-1R monoclonal antibody and is used to treat cancer; however, tumours can develop resistance to the therapy. Here, the authors show that the resistance is mediated by activation of STAT3 that results in an IGF2/IGF-2R signalling loop and recruitment of macrophages.
- Ji-Sun Lee
- Ju-Hee Kang
- Ho-Young Lee
